April 11, 2025 a 07:31 am
VTRS: Fundamental Ratio Analysis - Viatris Inc.
Viatris Inc. is a global healthcare company with a broad portfolio of products. Despite having a wide array of brands and collaborative agreements, the stock maintains a moderate performance in ratings. Investors should be cautious but may find opportunities in its diverse market segments.
Fundamental Rating
The fundamental analysis reveals mixed insights into Viatris Inc.'s financial health. Overall, the company shows strength in discounted cash flow (DCF) with room for improvement in other categories.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow (DCF) | 5 | |
| Return on Equity (ROE) | 1 | |
| Return on Assets (ROA) | 1 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 4 |
Historical Rating
An analysis of historical scores indicates stable yet constrained financial metrics, with minimal change over the last assessment period.
| Date | Overall | DCF | ROE | ROA | Debt to Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-04-10 | 2 | 5 | 1 | 1 | 1 | 1 | 4 |
| Previous | 0 | 5 | 1 | 1 | 1 | 1 | 4 |
Analyst Price Targets
The stock's price is predicted to have limited volatility as per the analysts, with estimates showing a narrow band between the high and low targets.
| High | Low | Median | Consensus |
|---|---|---|---|
| $15 | $12 | $14 | $13.75 |
Analyst Sentiment
The current consensus amongst analysts is to hold the stock, indicative of steady outlooks and moderate confidence in improvements.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 1 | |
| Hold | 7 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
Viatris Inc. presents a diversified product portfolio across multiple therapeutic areas, bolstered by strategic partnerships. Despite this, financial performance and market outlook remain moderate, as reflected by a "Hold" consensus from analysts. Opportunities may lie in its geographical and therapeutic expansion, but improvements in financial health are crucial. The price stability offers a degree of predictability, which could be appealing to risk-averse investors. In the near term, Viatris remains a cautious investment, with potential in the long term if it successfully leverages its collaborations and market presence.